Utilisation and safety of asenapine in secondary care in the United Kingdom: Results from the observational safety evaluation of asenapine (OBSERVA) study

被引：0
|
作者：
Dhanda, Sandeep [1 ,2 ]
Slade, Jan [1 ]
Osborne, Vicki [1 ]
Wise, Lesley [1 ]
Shakir, Saad [1 ,2 ]
机构：
[1] Drug Safety Res Unit, Southampton, Hants, England
[2] Univ Portsmouth, Portsmouth, Hants, England
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2018年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
593
引用
收藏
页码：272 / 273
页数：2
相关论文
共 50 条
  • [11] Utilisation and Safety of Deferasirox (Exjade®): Results from an Observational Cohort Study in England
    Osborne, Vicki
    Davies, Miranda
    Layton, Deborah
    Shakir, Saad A. W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 77 - 77
  • [12] Utilisation of Asenapine in the Mental Health Care Setting in England and Wales: First Results from a Specialist Cohort Event Monitoring (SCEM) Study
    Osborne, Vicki
    Slade, Jan
    Layton, Deborah
    Shakir, Saad A. W.
    Reilly, Joseph
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 87 - 87
  • [13] Utilisation and Safety of Deferasirox (Exjade®) in Older Adults: Results from an Observational Cohort Study in England
    Dhanda, S.
    Layton, D.
    Osborne, V.
    Shakir, S.
    DRUG SAFETY, 2017, 40 (10) : 978 - 978
  • [14] Primary safety results from the LEADLESS Observational Study
    Sperzel, Johannes
    Defaye, Pascal
    Delnoy, Peter-Paul
    Garcia Guerrero, Juan Jose
    Knops, Reinoud E.
    Tondo, Claudio
    Deharo, Jean-Claude
    Wong, Tom
    Neuzil, Petr
    EUROPACE, 2018, 20 (09): : 1491 - 1497
  • [15] Real-world treatment utilisation and safety of onabotulinumtoxinA for chronic migraine: results from an observational study in the European Union
    Matharu, M.
    Pascual, J.
    Nilsson-Remahl, I.
    Straube, A.
    Lum, A.
    Davar, G.
    Odom, D.
    Bennett, L.
    Proctor, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 115 - 115
  • [16] Factors Associated with Rivaroxaban Prescribing in Specialist Care Setting: Interim Results from the Rivaroxaban Observational Safety Evaluation (ROSE) Study
    Layton, Deborah
    Evans, Alison
    Davies, Miranda
    Osborne, Vicki
    Shakir, Saad A. W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 197 - 198
  • [17] EFFICACY AND SAFETY OF GOLIMUMAB INDUCTION FOR MODERATE TO SEVERE ULCERATIVE COLITIS IN THE UNITED KINGDOM: RESULTS FROM THE GOCOLITIS STUDY
    Probert, C.
    Gaya, D.
    Hamlin, P. J.
    Irving, P.
    Sebastian, S.
    Gillespie, G.
    Tate, H.
    Wheeler, C.
    GUT, 2016, 65 : A2 - A3
  • [18] Public attitudes towards motorcyclists' safety: A qualitative study from the United Kingdom
    Musselwhite, Charles B. A.
    Avineri, Erel
    Susilo, Yusak O.
    Bhattachary, Darren
    ACCIDENT ANALYSIS AND PREVENTION, 2012, 49 : 105 - 113
  • [19] Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia
    Cazorla, Pilar
    Mackle, Mary
    Zhao, Jun
    Ha, Xianwei
    Szegedi, Armin
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2012, 8 : 247 - 257
  • [20] Incidence of major and clinically relevant non-major (CRNM) bleeding in patients prescribed rivaroxaban in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
    Evans, Alison
    Davies, Miranda
    Wise, Lesley
    Shakir, Saad
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 456 - 457
12345